Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mydecine Innovations Group Inc (OP:MYCOF)

0.0053 +0.0026 (+96.30%)
Streaming Delayed Price Updated: 10:10 AM EDT, May 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 361
Open 0.0053
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0027
Today's Range 0.0053 - 0.0053
52wk Range 0.0007 - 0.0160
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
Global psychedelic drugs market to reach $10.2 billion by 2028, driven by mental health needs and evolving regulatory support. 
Via Benzinga
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
Via Benzinga

Performance

YTD
-13.1%
-13.1%
1 Month
+96.3%
+96.3%
3 Month
+47.2%
+47.2%
6 Month
N/A
N/A
1 Year
-62.7%
-62.7%

More News

Read More
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Board Approves Issuance of Shares for Debt Settlement
Via Investor Brand Network
Mydecine Innovations Group Inc. Announces Share for Debt Settlement
Via TheNewswire.com
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Via Benzinga
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Compounds Receive USPTO Notice of Allowances
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces USPTO Issues Notice of Allowance for MYCO-005 Compound
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property Product Safety
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
From Mydecine Innovations Group Inc.
Via GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Updates Special Access Program
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Files Prospectus Supplement, Closes Share Subscription Agreements
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Reports on Company Progress in Q4 2023 Update
Via Investor Brand Network
Exposures Product Safety
Mydecine Provides Q4 2023 Business Update
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Mydecine Innovations Group gearing up for human trials after completing Aquis listing
Via News Direct
Mydecine Innovations Group gearing up for human trials after completing Aquis listing
Via TheNewswire.com
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
Via Benzinga
Exposures Product Safety
Psychedelic-Based Drugs Biotech Company Begins Trading On UK's AQSE Growth Market
Via Benzinga
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Starts Trading on the AQSE Growth Market
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property Product Safety
Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings
From Mydecine Innovations Group Inc.
Via GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) Common Shares Begin Listing on CSE
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Expects UK Dual Listing Admission Next Month
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Receives CSE Listing Conditional Approval
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Mydecine Announces Conditional Approval of CSE Listing
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
Mydecine Releases Q2 2023: Developer Of Smoke Cessation Psilocybin Prodrugs & MDMA Analogs
Via Benzinga
Jamaica Launches Organic Psilocybin Gummies & New Psychedelic Retreat: Rose Hill's New Offer
Via Benzinga

Frequently Asked Questions

Is Mydecine Innovations Group Inc publicly traded?
Yes, Mydecine Innovations Group Inc is publicly traded.
What exchange does Mydecine Innovations Group Inc trade on?
Mydecine Innovations Group Inc trades on the OTC Traded
What is the ticker symbol for Mydecine Innovations Group Inc?
The ticker symbol for Mydecine Innovations Group Inc is MYCOF on the OTC Traded
What is the current price of Mydecine Innovations Group Inc?
The current price of Mydecine Innovations Group Inc is 0.0053
When was Mydecine Innovations Group Inc last traded?
The last trade of Mydecine Innovations Group Inc was at 05/28/25 10:10 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.